The present invention belongs to the field of medicine, relating to the field of antitumor drugs. Specifically to applications of substituent benzyloxy group containing ether compounds for preparing antitumor drugs.
The following journals and patents disclosed benzopyrone compounds containing methoxyacrylate with fungicidal activity in agrochemical field: Pest Management Science, Volume: 67, Issue: 6, Pages: 647-655; Natural Product Communications, Volume: 6, Issue: 12, Pages: 1917-1920; Nongyao, Volume: 50, Issue: 2, Pages: 90-92; Nongyaoxue Xuebao, Volume: 12, Issue: 4, Pages: 453-457; Natural Product Communications, Volume: 2, Issue: 8, Pages: 845-848; Chinese Chemical Letters, Volume: 22, Issue: 6, Pages: 663-666; WO 2005044813.
Journal of Medicinal Chemistry, Volume: 50, Issue: 12, Pages: 2886-2895 reported the following general formula containing benzopyrone group with antiplatelet activity.
Bioorganic & Medicinal Chemistry Letters 23(2013) 3505-3510 disclosed a strobilurin compound containing substituted pyrimidinamines with some antitumor activity, the structure of compound 96 (compound A in this patent) is as follows:
Patent U.S. Pat. No. 6,084,120 disclosed the compound having following general formula has some inhibition effect on Plasmodium falciparum NF54 strain and plasmodium berghei, however, compound B was reported at the same time without any biological data. Patent U.S. Pat. No. 7,947,734 also disclosed compound B (that is flufenoxystrobin) with good fungicidal and acaricidal activity in agrochmical field.
In the prior art, the substituent benzyloxy group containing ether compounds having the structure of general formula I were not reported as antitumor agents.
The object of the present invention is to provide substituent benzyloxy group containing ether compounds having general formula I, which can be applied to prepare antitumor drugs.
Detailed Description of the Invention is as Follows:
The application of substituent benzyloxy group containing ether compounds for preparing antitumor drugs, the compounds having the structure of general formula I:
Wherein:
Ar is selected from one of the following groups, Ar1 to Ar16:
Q is selected from one of the following groups, Q1 to Q22:
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C12alkyl, C1-C12haloalkyl, C3-C8cycloalkyl, C1-C12alkoxy, C1-C12haloalkoxy, C1-C12alkylthio, C1-C12haloalkylthio, C1-C12alkoxyC1-C12alkyl haloC1-C12alkoxyC1-C12alkyl
C1-C12alkoxyC1-C12alkoxy
haloC1-C12alkoxyC1-C12alkoxy
C1-C12alkylthioC1-C12alkyl
haloC1-C12alkylthioC1-C12alkyl
C1-C12alkylamino
C1-C12haloalkylamino
C2-C12dialkylamino
C2-C12halodialkylamino
piperidinyl
pyrrolidinyl
N-methylpiperidinyl
morpholinyl
C2-C12alkenyl
C2-C12haloalkenyl
C2-C12alkynyl
C2-C12haloalkynyl
C2-C12alkenyloxy
C2-C12haloalkenyloxy
C2-C12alkynyloxy
C2-C12haloalkynyloxy
C1-C12alkylsulfonyl
C1-C12haloalkylsulfonyl
C1-C12alkylsulfinyl
C1-C12haloalkylsulfinyl
C1-C12alkylcarbonyl
C1-C12haloalkylcarbonyl
C1-C12alkylcarbonyloxy
C1-C12alkylcarbonylamino
C1-C12alkylsulfonyloxy
C1-C12alkoxycarbonyl
C1-C12haloalkoxycarbonyl
C1-C12alkylaminosulfonyl
C1-C12alkoxycarbonylamino
C1-C12alkoxycarbonylC1-C12alkyl
C1-C12alkoxycarbonylC1-C12alkoxy
aminoC1-C12alkyl
C1-C12alkylaminoC1-C12alkyl
C2-C12dialkylaminoC1-C12alkyl
C(═O)NR10R11
OC(═O)NR10R11
C(═S)NR10R11
SO2NR10R11
C(═NOR9)R8 or R7; or R1, R2 and carbon atom linked to them form five, six or seven-membered ring;
R7 is selected from unsubstituted or substituted phenyl, phenyloxy, phenyloxy C1-C12alkyl phenylcarbonyl
phenyloxycarbonyl
phenylaminocarbonyl
phenylC1-C12alkyl
phenylC1-C12alkoxy
phenylC1-C12alkoxyC1-C12alkyl
naphthyl
naphthyloxy
naphthyloxy C1-C12alkyl
naphthylcarbonyl
naphthyl C1-C12alkyl
naphthyl C1-C12alkoxy
naphthyl C1-C12alkoxyC1-C12alkyl
heteroaryl
heteroaryloxy
heteroarylC1-C12alkoxyC1-C12alkyl
heteroaryloxyC1-C12alkyl
heteroarylcarbonyl
heteroaryloxycarbonyl
heteroarylaminocarbonyl
heteroarylC1-C12alkyl or heteroarylC1-C12alkoxy, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo
NO2
CN
SH
C1-C6alkyl
C1-C6 halo alkyl
C3-C8cycloalkyl
C1-C6alkoxy
C1-C6 halo alkoxy
C1-C6alkylthio
C1-C6 halo alkylthio
C2-C6alkenyl
C2-C6 halo alkenyl
C2-C6alkynyl
halo alkynyl
C3-C6alkenyloxy
C3-C6 halo alkenyloxy
C3-C6alkynyloxy
C3-C6 halo alkynyloxy
C1-C6alkylsulfinyl
C1-C6 halo alkylsulfinyl
C1-C6alkylsulfonyl
C1-C6 halo alkylsulfonyl
C1-C6alkoxyC1-C6alkyl
C1-C6alkylcarbonyl
C1-C6 halo alkylcarbonyl
C1-C6alkylcarbonyloxy
C1-C6alkylcarbonylamino
C1-C6alkylsulfonyloxy
C1-C6alkoxycarbonyl
C1-C6alkoxyC1-C6alkoxy
C1-C6alkoxycarbonylC1-C6alkyl
C1-C6alkoxycarbonylamino
C1-C6alkoxycarbonylC1-C6alkoxy
CHO
CO2H
CO2Na
CO2NH4
NR10R11
C(═O)NR10R11
OC(═O)NR10R11
C(═S)NR10R11 or SO2NR10R11:
R8, R9 is mutually independently selected from H C1-C6alkyl
aryl or aryl C1-C6 alkyl;
R10, R11 mutually independently may be the same or different selected from H
C1-C6alkyl
C1-C6 halo alkyl
C1-C6alkoxy
C1-C6 halo alkoxy
C1-C6alkylthio
C1-C6 halo alkylthio or C3-C8cycloalkyl;
And their stereoisomers.
The preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1 Ar2
Ar3
Ar4 or Ar16;
Q is selected from Q1 Q2
Q3
Q4
Q5
Q6
Q7
Q8
Q9
Q19
Q20
Q21 or Q22:
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C1-C6alkoxy, C1-C6haloalkoxy, C1-C6alkylthio, C1-C6haloalkylthio, C1-C6alkoxyC1-C6alkyl haloC1-C6alkoxyC1-C6alkyl
C1-C6alkoxyC1-C6alkoxy
haloC1-C6alkoxyC1-C6alkoxy
C1-C6alkylthioC1-C6alkyl
haloC1-C6alkylthioC1-C6alkyl
C1-C6alkylamino
C1-C6haloalkylamino
C2-C8dialkylamino
C2-C8halodialkylamino
piperidinyl
pyrrolidinyl
N-methylpiperidinyl
morpholinyl
C2-C6alkenyl
C2-C6haloalkenyl
C2-C6alkynyl
C2-C6haloalkynyl
C2-C6alkenyloxy
C2-C6haloalkenyloxy
C2-C6alkynyloxy
C2-C6haloalkynyloxy
C1-C6alkylsulfonyl
C1-C6haloalkylsulfonyl
C1-C6alkylsulfinyl
C1-C6haloalkylsulfinyl
C1-C6alkylcarbonyl
C1-C6haloalkylcarbonyl
C1-C6alkylcarbonyloxyl
C1-C6alkylcarbonylamino
C1-C6alkylsulfonyloxy
C1-C6alkoxycarbonyl
C1-C6haloalkoxycarbonyl
C1-C6alkylaminosulfonyl
C1-C6alkoxycarbonylamino
C1-C6alkoxycarbonylC1-C6alkyl
C1-C6alkoxycarbonylC1-C6alkoxy
aminoC1-C6alkyl
C1-C6alkylaminoC1-C6alkyl
C2-C8dialkylaminoC1-C6alkyl
C(═O)NR10R11
OC(═O)NR10R11
C(═S)NR10R11
SO2NR10R11, C(═NOR9) R8 or R7; or R1, R2 and carbon atom linked to them form five or six-membered ring;
R7 is selected from unsubstituted or substituted phenyl, phenyloxy, phenyloxy C1-C6alkyl phenylcarbonyl
phenyloxycarbonyl
phenylaminocarbonyl
phenylC1-C6alkyl
phenylC1-C6alkoxy
phenylC1-C6alkoxyC1-C6alkyl
naphthyl
naphthyloxy
naphthyloxy C1-C6alkyl
naphthylcarbonyl
naphthyl C1-C6alkyl
naphthyl C1-C6alkoxy
naphthylC1-C6alkoxyC1-C6alkyl
heteroaryl
heteroaryloxy
heteroarylC1-C6alkoxyC1-C6alkyl
heteroaryloxyC1-C6alkyl
heteroarylcarbonyl
heteroaryloxycarbonyl
heteroarylaminocarbonyl
heteroarylC1-C6alkyl or heteroarylC1-C6alkoxy, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo
NO2
SH
C1-C4alkyl
C1-C4 haloalkyl
C3-C6cycloalkyl
C1-C4alkoxy
C1-C4 halo alkoxy
C1-C4alkylthio
C1-C4 halo alkylthio
C2-C4alkenyl
C2-C4 halo alkenyl
C2-C4alkynyl
C2-C4 halo alkynyl
C3-C4alkenyloxy
C3-C4halo alkenyloxy
C3-C4alkynyloxy
C3-C4 halo alkynyloxy
C1-C4alkylsulfinyl
C1-C4 halo alkylsulfinyl
C1-C4alkylsulfonyl
C1-C4 halo alkylsulfonyl
C1-C4alkoxyC1-C4alkyl
C1-C4alkylcarbonyl
C1-C4 halo alkylcarbonyl
C1-C4alkylcarbonyloxy
C1-C4alkylcarbonylamino
C1-C4alkylsulfonyloxy
C1-C4alkoxycarbonyl
C1-C4alkoxyC1-C4alkoxy
C1-C4alkoxycarbonylC1-C4alkyl
C1-C4alkoxycarbonylamino
C1-C4alkoxycarbonylC1-C4alkoxy
CHO
CO2H
CO2Na
CO2NH4
NR10R11
C(═O)NR10R11
OC(═O)NR10R11
C(═S)NR10R11 or SO2NR10R11:
R8, R9 is mutually independently selected from H C1-C4alkyl
aryl or aryl C1-C4alkyl;
R10, R11 mutually independently may be the same or different selected from C1-C4alkyl
C1-C4 halo alkyl
C1-C4alkoxy
C1-C4 halo alkoxy
C1-C4alkylthio
C1-C4 halo alkylthio or C3-C6cycloalkyl.
The preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1, Ar2, Ar3, Ar4 or Ar16;
Q is selected from Q1 Q2
Q3
Q4
Q5
Q6
Q7
Q8
Q9
Q19
Q20
Q21
or Q22:
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, NO2, OH, NH2, CHO, CO2H, CO2Na, CO2NH4, C1-C6alkyl, C1-C6haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, C1-C4haloalkylthio, C1-C4alkoxyC1-C4alkyl haloC1-C4alkoxyC1-C4alkyl
C1-C4alkoxyC1-C4alkoxy
haloC1-C4alkoxyC1-C4alkoxy
C1-C4alkylthioC1-C4alkyl
haloC1-C4alkylthioC1-C4alkyl
C1-C4alkylamino
C1-C4haloalkylamino
C2-C6dialkylamino
C2-C6halodialkylamino
piperidinyl
pyrrolidinyl
N-methylpiperidinyl
morpholinyl
C2-C4alkenyl
C2-C4haloalkenyl
C2-C4alkynyl
C2-C4haloalkynyl
C2-C4alkenyloxy
C2-C4haloalkenyloxy
C2-C4alkynyloxy
C2-C4haloalkynyloxy
C1-C4alkylsulfonyl
C1-C4haloalkylsulfonyl
C1-C4alkylsulfinyl
C1-C4haloalkylsulfinyl
C1-C4alkylcarbonyl
C1-C4haloalkylcarbonyl
C1-C4alkylcarbonyloxy
C1-C4alkylcarbonylamino
C1-C4alkylsulfonyloxy
C1-C4alkoxycarbonyl
C1-C4haloalkoxycarbonyl
C1-C4alkylaminosulfonyl
C1-C4alkoxycarbonylamino
C1-C4alkoxycarbonylC1-C4alkyl
C1-C4alkoxycarbonylC1-C4alkoxy
aminoC1-C4alkyl
C1-C4alkylaminoC1-C4alkyl
C2-C6dialkylaminoC1-C4alkyl
C(═O)NR10R11
OC(═O)NR10R11
C(═S)NR10R11
SO2NR10R11
C(═NOR9)R8 or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
R7 is selected from unsubstituted or substituted phenyl phenyloxy
phenyloxy C1-C4alkyl
phenylcarbonyl
phenyloxycarbonyl
phenylaminocarbonyl
phenylC1-C4alkyl
phenylC1-C4alkoxy
phenylC1-C4alkoxyC1-C4alkyl
naphthyl
naphthyloxy
naphthyloxy C1-C4alkyl
naphthylcarbonyl
naphthyl C1-C4alkyl
naphthyl C1-C4alkoxy
naphthylC1-C4alkoxyC1-C4alkyl
heteroaryl
heteroaryloxy
heteroarylC1-C4alkoxyC1-C4alkyl
heteroaryloxyC1-C4alkyl
heteroarylcarbonyl
heteroaryloxycarbonyl
heteroarylaminocarbonyl
heteroarylC1-C4alkyl or heteroarylC1-C4alkoxy
which is further mutually independently optionally substituted by 1 to 5 following group(s): halo
NO2
CN
SH
C1-C4alkyl
C1-C4 haloalkyl
C3-C6cycloalkyl
C1-C4alkoxy
C1-C4haloalkoxy
C1-C4alkylthio
C1-C4 halo alkylthio
C2-C4alkenyl
C2-C4 halo alkenyl
C2-C4alkynyl
C2-C4 halo alkynyl
C3-C4alkenyloxy
C3-C4halo alkenyloxy
C3-C4alkynyloxy
C3-C4 haloalkynyloxy
C1-C4alkylsulfinyl
C1-C4 halo alkylsulfinyl
C1-C4alkylsulfonyl
C1-C4 halo alkylsulfonyl
C1-C4alkoxyC1-C4alkyl
C1-C4alkylcarbonyl
C1-C4 halo alkylcarbonyl
C1-C4alkylcarbonyloxy
C1-C4alkylcarbonylamino
C1-C4alkylsulfonyloxy
C1-C4alkoxycarbonyl
C1-C4alkoxyC1-C4alkoxy
C1-C4alkoxycarbonylC1-C4alkyl
C1-C4alkoxycarbonylamino
C1-C4alkoxycarbonylC1-C4alkoxy
CHO
CO2H
CO2Na
CO2NH4
NR10R11
C(═O)NR10R11
OC(═O)NR10R11
C(═S)NR10R11 or SO2NR10R11:
R8, R9 is mutually independently selected from H C1-C4alkyl
aryl or aryl C1-C4alkyl;
R10, R11 mutually independently may be the same or different selected from H
C1-C4alkyl
C1-C4 haloalkyl
C1-C4alkoxyl
C1-C4 haloalkoxy
C1-C4alkylthio
C1-C4 haloalkylthio or C3-C6cycloalkyl.
Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1 Ar2
Ar3 or Ar16;
Q is selected from Q1 Q2
Q3
Q4
Q5
Q6
Q7 or Q8;
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, C1-C6alkyl, C1-C4haloalkyl, C3-C6cycloalkyl, C1-C4alkoxy, C1-C4haloalkoxy, C1-C4alkylthio, C1-C4alkoxyC1-C4alkyl C1-C4alkylamino
C2-C6dialkylamino
C1-C4alkylsulfonyl or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar1, Ar2, Ar3 or Ar16;
Q is Q1;
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, C1-C6alkyl, C1-C4haloalkyl or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Ar is selected from Ar3 or Ar16;
Q is Q1;
R1, R2, R3, R4, R5, R6 mutually independently may be the same or different, selected from H, halo, CN, C1-C6alkyl, C1-C4haloalkyl or R7; or R1, R2 and carbon atom linked to them form saturated five or six-membered ring;
R7 is selected from unsubstituted or substituted phenyl, benzyl or heteroaryl, which is further mutually independently optionally substituted by 1 to 5 following group(s): halo NO2
CN
C1-C4alkyl
C1-C4 haloalkyl
C1-C4alkoxy or C1-C4 haloalkoxy.
Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
Furthermore, the preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
The more preferred substituent benzyloxy group containing ether compounds above compounds applied as antitumor drugs of general formula I of this invention are:
The most preferred substituent benzyloxy group containing ether compounds applied as antitumor drugs of general formula I of this invention are:
The terms used above to definite the compounds of general formula I represent substitutes as follow:
The “halogen” or “halo” is fluorine, chlorine, bromine or iodine.
The “alkyl” stands for straight or branched chain alkyl, such as methyl, ethyl, propyl, isopropyl or tert-butyl. The “haloalkyl” stands for straight or branched chain alkyl, in which hydrogen atoms can be all or partly substituted with halogen, such as chloromethyl, dichloromethyl, trichlororaethyl, fluoromethyl, difluoromethyl, trifluoromethyl, etc.
The “alkoxy” refers to straight or branched chain alkyl, which is linked to the structure by oxygen atom. The “haloalkoxy” refers to straight or branched chain alkoxy, in which hydrogen atoms may be all or partly substituted with halogen, such as chloromethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, trifluoroethoxy, etc.
The “alkylthio” refers to straight or branched chain alkyl, which is linked to the structure by sulfur atom. The “haloalkylthio” refers to straight or branched chain alkylthio, in which hydrogen atoms may be all or partly substituted with halogen, such as chloromethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, etc.
The “alkoxyalkyl” means alkoxy is linked to the structure by alkyl. Such as —CH2OCH2, —CH2OCH2CH3.
The “haloalkoxyalkyl” refers to alkoxyalkyl, in which hydrogen atoms may be all or partly substituted with halogen, such as —CH2OCH2CH2Cl.
The “alkoxyalkoxy” means OCH2OCH2CH3 etc. The “haloalkoxyalkoxy” means —OCH2OCH2CH2Cl etc.
The “alkylthioalkyl” means alkylthio is linked to the structure by alkyl. Such as —CH2SCH2.
The “haloalkylthioalkyl” means haloalkylthio is linked to the structure by alkyl.
The “alkylamino” refers to straight or branched chain alkyl, which is linked to the structure by nitrogen atom.
The “haloalkylamino” refers to straight or branched chain alkylamino, in which hydrogen atoms may be all or partly substituted with halogen.
The alkenyl refers to straight or branched chain alkenyl, such as ethenyl, 1-propenyl, 2-propenyl and different isomer of butenyl, pentenyl and hexenyl. Alkenyl also includes polyene, such as propa-1,2-dienyl and hexa-2,4-dienyl. The haloalkenyl stands for straight or branched chain alkenyl, in which hydrogen atoms can be all or partly substituted with halogen. The alkynyl refers to straight or branched chain alkynyl, such as ethynyl, 1-propynyl and different isomer of butynyl, pentynyl and hexynyl. Alkynyl also includes groups including more than one triple bonds, such as hexa-2,5-diynyl. The “haloalkynyl” stands for straight or branched chain alkynyl, in which hydrogen atoms can be all or partly substituted with halogen.
The alkenoxyl refers to straight or branched chain alkynes is linked to the structure by oxygen, such as propenyloxy. The haloalkenoxyl stands for a straight-chain or branched alkenoxyl, in which hydrogen atoms may be all or partly substituted with halogen. The alkynoxyl refers to straight or branched chain alkynes is linked to the structure by oxygen, such as propynyloxy. The haloalkynoxyl stands for a straight-chain or branched alkynoxyl, in which hydrogen atoms may be all or partly substituted with halogen.
The “alkylsulfonyl” means a straight-chain or branched alkyl is linked to the structure by (—SO2—), such as methylsulfonyl. The “haloalkylsulfonyl” stands for a straight-chain or branched alkylsulfonyl, in which hydrogen atoms may be all or partly substituted with halogen.
The “alkylsulfinyl” means a straight-chain or branched alkyl is linked to the structure by (—SO—), such as methylsulfinyl.
The “haloalkylsulfinyl” stands for a straight-chain or branched alkylsulfinyl, in which hydrogen atoms may be all or partly substituted with halogen.
The “alkylcarbonyl” means alkyl is linked to the structure by carbonyl. such as CH3CO—, CH3CH2CO—.
The “haloalkylcarbonyl” stands for a straight-chain or branched alkylcarbonyl, in which hydrogen atoms may be all or partly substituted with halogen, such as CF3CO—.
The “alkylcarbonyloxy” means CH3COO—, CH3CH2NHCOO— etc. The “alkylcarbonylamino” means CH3CONH—, CH3CH2NHCONH— etc.
The “alkylsulfonyloxy” means alkyl-S(O)2—O—. The “alkoxycarbonyl” means alkyl-O—CO—.
The “haloalkoxycarbonyl” stands for alkoxycarbonyl, in which hydrogen atoms can be all or partly substituted with halogen, such as —COOCH2CF3, —COOCH2CH2Cl.
The “alkylaminosulfonyl” means —S(O)2NHCH3, —S(O)2NHCH2CH3 etc. The “alkoxycarbonylamino” means —NHCOOCH3, —NHCOOCH2CH3 etc. The “alkoxycarbonylalkyl” means —CH2COOCH3, —CH2COOCH2CH3 etc. The “alkoxycarbonylalkoxy” means —OCH2COOCH3, —OCH2COOCH2CH3 etc. The “aminoalkyl” such as —CH2NH2, —CH2CH2NH2. The “alkylaminoalkyl” such as CH2NHCH3, —CH2NHCH2CH3. The “dialkylaminoalkyl” such as —CH2NH(CH3)2 etc.
The “aryl” in terms of (hetero)aryl, (hetero)aryloxy, (hetero)arylalkoxyalkyl, (hetero)aryloxyalkyl, (hetero)arylcarbonyl, (hetero)aryloxycarbonyl, (hetero)arylaminocarbonyl, (hetero)arylalkyl or (hetero)arylalkoxy include phenyl or naphthyl etc.
The heteroaryl stands for five member ring or six member ring containing one or more N, O, S hetero atoms. Such as pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, thiazolyl, quinolinyl, isothiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrazolyl, pyranyl, triazolyl, tetrazolyl, benzothiazolyl, benzofuranyl, etc. The (hetero)aryloxy such as phenyloxy, pyridinyloxy, pyrimidinyloxy, quinolinyloxy, eye.
The (hetero)arylalkoxyalkyl means —CH2OCH2Ph, 6-chloropyridin-3-ylmethoxyl, etc. The (hetero)aryloxyalkyl means, —CH2OPh, 4,6-(OCH3)2-2-yloxyethyl, etc. The (hetero)arylcarbonyl means PhCHO, 4-ClPhCHO, etc. The (hetero)aryloxycarbonyl means PhOCO, 4-ClPhOCO, 4-NO2PhOCO, Naph OCO, etc. The (hetero)arylaminocarbonyl, (hetero)arylalkyl or (hetero)arylalkoxy includes phenyl or naphthyl etc.
The compounds of the present invention can form stereoisom (Z- and E-isomer respectively) due to the existing of C═C and C═N bonds. The invention includes Z-isomer and E-isomer and their mixture at any ratio.
The drugs were made from the active ingredients of general formula I substituent benzyloxy group containing ether compounds, which can dose by oral medication or parenteral route, also by implantable medication pump and other methods.
The substituent benzyloxy group containing ether compounds having the general formula I in present invention can be used to prepare the drugs for curing or alleviating the cancer. The formulations include tablets, pills, capsule, granule, syrup, injection or freeze-dried powder injection.
Furthermore, the substituent benzyloxy group containing ether compounds having the general formula I in present invention can be used to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The cancers include but not limited to colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer or stomach cancer.
Part of the substitutes of R1, R2, R3, R4, R5 and R6 in formula I are separately listed in table 1, but without being restricted thereby.
The present invention is also explained by the following compounds having general formula I with antitumor activity in Table 2-Table 53, but without being restricted thereby.
When Ar is Ar1, Q is Q1, the presentitive compounds 2-1 to 2-112 are listed in Table 2.
Table 3: When Ar is Ar1, Q is Q2, the substituents of presentitive compounds 3-1 to 3-112 are consistent with 2-1 to 2-112 in Table 2;
Table 4: When Ar is Ar1, Q is Q3, the substituents of presentitive compounds 4-1 to 4-112 are consistent with 2-1 to 2-112 in Table 2;
Table 5: When Ar is Ar1, Q is Q4, the substituents of presentitive compounds 5-1 to 5-112 are consistent with 2-1 to 2-112 in Table 2;
Table 6: When Ar is Ar1, Q is Q5, the substituents of presentitive compounds 6-1 to 6-112 are consistent with 2-1 to 2-112 in Table 2;
Table 7: When Ar is Ar1, Q is Q6, the substituents of presentitive compounds 7-1 to 7-112 are consistent with 2-1 to 2-112 in Table 2;
Table 8: When Ar is Ar1, Q is Q7, the substituents of presentitive compounds 8-1 to 8-112 are consistent with 2-1 to 2-112 in Table 2;
Table 9: When Ar is Ar1, Q is Q8 is the substituents of presentitive compounds 9-1 to 9-112 are consistent with 2-1 to 2-112 in Table 2;
Table 10: When Ar is Ar1, Q is Q9, the substituents of presentitive compounds 10-1 to 10-112 are consistent with 2-1 to 2-112 in Table 2;
Table 11: When Ar is Ar1, Q is Q19, the substituents of presentitive compounds 11-1 to 11-112 are consistent with 2-1 to 2-112 in Table 2;
Table 12: When Ar is Ar1, Q is Q20, the substituents of presentitive compounds 12-1 to 12-112 are consistent with 2-1 to 2-112 in Table 2;
Table 13: When Ar is Ar1, Q is Q21, the substituents of presentitive compounds 13-1 to 13-112 are consistent with 2-1 to 2-112 in Table 2;
Table 14: When Ar is Ar1, Q is Q22, the substituents of presentitive compounds 14-1 to 14-112 are consistent with 2-1 to 2-112 in Table 2.
When Ar is Ar2, Q is Q1, the presentitive compounds 15-1 to 15-121 are listed in Table 15.
Table 16: When Ar is Ar2, Q is Q2, the substituents of presentitive compounds 16-1 to 16-121 are consistent with 15-1 to 15-121 in Table 15;
Table 17: When Ar is Ar2, Q is Q3, the substituents of presentitive compounds 17-1 to 17-121 are consistent with 15-1 to 15-121 in Table 15;
Table 18: When Ar is Ar2, Q is Q4, the substituents of presentitive compounds 18-1 to 18-121 are consistent with 15-1 to 15-121 in Table 15;
Table 19: When Ar is Ar2, Q is Q5, the substituents of presentitive compounds 19-1 to 19-121 are consistent with 15-1 to 15-121 in Table 15;
Table 20: When Ar is Ar2, Q is Q6, the substituents of presentitive compounds 20-1 to 20-121 are consistent with 15-1 to 15-121 in Table 15;
Table 21: When Ar is Ar2, Q is Q7, the substituents of presentitive compounds 21-1 to 21-121 are consistent with 15-1 to 15-121 in Table 15;
Table 22: When Ar is Ar2, Q is Q8, the substituents of presentitive compounds 22-1 to 22-121 are consistent with 15-1 to 15-121 in Table 15;
Table 23: When Ar is Ar2, Q is Q9, the substituents of presentitive compounds 23-1 to 23-121 are consistent with 15-1 to 15-121 in Table 15;
Table 24: When Ar is Ar2, Q is Q19, the substituents of presentitive compounds 24-1 to 24-121 are consistent with 15-1 to 15-121 in Table 15;
Table 25: When Ar is Ar2, Q is Q20, the substituents of presentitive compounds 25-1 to 25-121 are consistent with 15-1 to 15-121 in Table 15;
Table 26: When Ar is Ar2, Q is Q21, the substituents of presentitive compounds 26-1 to 26-121 are consistent with 15-1 to 15-121 in Table 15;
Table 27: When Ar is Ar2, Q is Q22, the substituents of presentitive compounds 27-1 to 27-121 are consistent with 15-1 to 15-121 in Table 15;
When Ar is Ar3, Q is Q1, the presentitive compounds 28-1 to 28-139 are listed in Table 28.
Table 29: When Ar is Ar3, Q is Q2, the substituents of presentitive compounds 29-1 to 29-131 are consistent with 28-1 to 28-139 in Table 28;
Table 30: When Ar is Ar3, Q is Q3, the substituents of presentitive compounds 30-1 to 30-131 are consistent with 28-1 to 28-139 in Table 28;
Table 31: When Ar is Ar3, Q is Q4, the substituents of presentitive compounds 31-1 to 31-131 are consistent with 28-1 to 28-139 in Table 28;
Table 32: When Ar is Ar3, Q is Q5, the substituents of presentitive compounds 32-1 to 32-131 are consistent with 28-1 to 28-139 in Table 28;
Table 33: When Ar is Ar3, Q is Q6, the substituents of presentitive compounds 33-1 to 33-131 are consistent with 28-1 to 28-139 in Table 28;
Table 34: When Ar is Ar3, Q is Q7, the substituents of presentitive compounds 34-1 to 34-131 are consistent with 28-1 to 28-139 in Table 28;
Table 35: When Ar is Ar3, Q is Q8, the substituents of presentitive compounds 35-1 to 35-131 are consistent with 28-1 to 28-139 in Table 28;
Table 36: When Ar is Ar3, Q is Q9, the substituents of presentitive compounds 36-1 to 36-131 are consistent with 28-1 to 28-139 in Table 28;
Table 37: When Ar is Ar3, Q is Q19, the substituents of presentitive compounds 37-1 to 37-131 are consistent with 28-1 to 28-139 in Table 28;
Table 38: When Ar is Ar3, Q is Q20, the substituents of presentitive compounds 38-1 to 38-131 are consistent with 28-1 to 28-139 in Table 28;
Table 39: When Ar is Ar3, Q is Q21, the substituents of presentitive compounds 39-1 to 39-131 are consistent with 28-1 to 28-139 in Table 28;
Table 40: When Ar is Ar3, Q is Q22, the substituents of presentitive compounds 40-1 to 40-131 are consistent with 28-1 to 28-139 in Table 28.
When Ar is Ar4, Q is Q1, the presentitive compounds 41-1 to 41-116 are listed in Table 41.
Table 42: When Ar is Ar4, Q is Q2, the substituents of presentitive compounds 42-1 to 42-116 are consistent with 41-1 to 41-116 in Table 41;
Table 43: When Ar is Ar4, Q is Q3, the substituents of presentitive compounds 43-1 to 43-116 are consistent with 41-1 to 41-116 in Table 41;
Table 44: When Ar is Ar4, Q is Q4, the substituents of presentitive compounds 44-1 to 44-116 are consistent with 41-1 to 41-116 in Table 41;
Table 45: When Ar is Ar4, Q is Q5, the substituents of presentitive compounds 45-1 to 45-116 are consistent with 41-1 to 41-116 in Table 41;
Table 46: When Ar is Ar4, Q is Q6, the substituents of presentitive compounds 46-1 to 46-116 are consistent with 41-1 to 41-116 in Table 41;
Table 47: When Ar is Ar4, Q is Q7, the substituents of presentitive compounds 47-1 to 47-116 are consistent with 41-1 to 41-116 in Table 41;
Table 48: When Ar is Ar4, Q is Q8, the substituents of presentitive compounds 48-1 to 48-116 are consistent with 41-1 to 41-116 in Table 41;
Table 49: When Ar is Ar3, Q is Q9, the substituents of presentitive compounds 49-1 to 49-116 are consistent with 41-1 to 41-116 in Table 41;
Table 50: When Ar is Ar3, Q is Q19, the substituents of presentitive compounds 50-1 to 50-116 are consistent with 41-1 to 41-116 in Table 41;
Table 51: When Ar is Ar3, Q is Q20, the substituents of presentitive compounds 51-1 to 51-116 are consistent with 41-1 to 41-116 in Table 41;
Table 52: When Ar is Ar3, Q is Q21, the substituents of presentitive compounds 52-1 to 52-116 are consistent with 41-1 to 41-116 in Table 41;
Table 53: When Ar is Ar3, Q is Q22, the substituents of presentitive compounds 53-1 to 53-116 are consistent with 41-1 to 41-116 in Table 41.
Some commercial (or under development) substituent benzyloxy group containing ether compounds used as fungicides in agrochemical field are summarized as follows (Table 54):
The most preferred substituent benzyloxy group containing ether compounds applied as antitumor drugs of general formula I are: compounds 28-5 (jiaxiangjunzhi), 28-72 (coumoxystrobin), 28-18, 28-128, 28-129 and pyraoxystrobin.
The compounds having formula I in present invention have been reported in prior art, which are commercial available or can be prepared according to the following literatures U.S. Pat. No. 7,642,364, CNP1869032, Pest Manag. Sci. 2011, 67, 647, Nat. Prod. Commun. 2011, 6, 1917, Chin. Chem. Lett. 2011, 22, 663, Chin. J. Pestic. 2011, 50, 90.
The present invention includes the formulations, which were made from the compounds having the general formula I as active ingredient, and preparation thereof. The preparation of formulations: Dissolve the compounds of present invention in water soluble organic solvents, the non-ionicity of surfactant, water soluble lipid, all kinds of cyclodextrin, fatty acid, fatty acid ester, phospholipids or their combination solvents, then 1-20% of carbohydrates were obtained by adding physiological saline. Mentioned organic solvents include polyethylene glycol (PEG), ethanol, propylene glycol or their combination solvents.
The compounds having the general formula I in present invention and their isomers and prodrug can be used to prepare the drugs or formulations to cure, prevent or alleviate cancer. The active ingredients are composed of one or more than two substituent benzyloxy group containing ether compounds having the general formula I. Especially to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The preferred cancers are: colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer, or stomach cancer, etc.
The compounds in present invention can be used as active ingredients of antitumor drug, which can be used alone or combined with other antitumor/antiviral drugs. The drug combination process in present invention, using at least one of the compounds and its active derivatives with other one or more antitumor/antiviral drugs, are used together to increase the overall effect. The dose and drug administration time of combination therapy are based on the most reasonable treatment effect in the different situations.
The formulations include the effective dose of the compounds having general formula I. The “effective dose” refers to the compound dosage, which are effective to cure cancer. The effective dose or dose can be different based on the suggestions of experienced person at different conditions. For instance, the different usage of drug based on different cancers; the dose of drug also can be changed based on whether it shares with other therapeutic method, such as antitumor or antiviral drugs. The drug can be prepared for any useable formulations. The salts of compounds also can be used if the alkaline or acidic compounds can formed the non-toxic acids or salts. The organic acids/salts in pharmacy include anion salts, which are formed with acids, such as p-toluenesulfonic acid, methylsulfonic acid, acetic acid, benzoic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, ascorbic acid or glycerophosphoric acid; the inorganic salts include chloride, bromide, fluoride, iodide, sulfate, nitrate, bicarbonate, carbonate or phosphate. For example, the alkaline compounds, such as amines can form salts with suitable acids; acids can form salts with alkalis or alkaline earth.
The compounds in present invention having general formula I general easily dissolve in organic solvent, water soluble solvent and their mixture with water. The water soluble solvents prefer alcohol, polyethylene glycol, N-methyl-2-pyrrolidone, N, N-dimethyl acetamide, N, N-dimethyl formamide, dimethylsulfoxide, acetonitrile and their mixture. Mentioned alcohols prefer methanol, ethanol, isopropanol, glycerol or ethylene glycol. The compounds in present invention mix with common drug carrier to form formulations. Dissolve the compounds of present invention in water soluble organic solvents, aprotic solvent, water soluble lipid, cyclodextrin, fatty acid, phospholipids or their combination solvents, then 1-20% of carbohydrates were obtained by adding physiological saline, such as glucose aqueous solution. The stability formulations made by this way are used for animal and clinical.
The drugs were made from the active ingredients of general formula I compounds, which can dose by oral medication or parenteral route, also by implantable medication pump and other methods. Where the parenteral route refer to injection or drip technology through subcutaneous intradermal, intramuscular, intravenous, arteries, atrium, synovium, sternum, intrathecal, wound area, encephalic, etc. The formulations were mixed using conventional method by technicist, which are used for animal and clinical, including tablets, pills, capsule, granule, syrup, injection, freeze-dried powder injection, emulsion, powder, freeze-dried powder, drop pill, milk suspension, aqueous suspension, colloid, colloidal solution, sustained-release suspensions, nanoparticle or other formulations.
The compounds having the general formula I in present invention can be used to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The cancers include but not limited to colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer or stomach cancer.
The present invention is illustrated by the following examples, but without being restricted thereby. (All raw materials are commercially available unless otherwise specified.)
Antitumor Activity Bioassay
In vitro Cell inhibition assay is as follows:
The human cancer cell lines used for this assay were bladder cancer J82, T24, prostate cancer LNCap, PC-3, lung cancer A549, H157, H460, H520, colon cancer HCT8, HCT116, RkO, and leukemia HL-60, etc.
In vitro cell culture technology was selected for the determination of inhibition rate bladder cancer cell lines J82 and T24, prostate cancer cell lines LNCap and PC-3, lung cancer cell lines A549, H157, H460 and H520. 1000 to 3000 cells were inoculated to 24-well plate, followed by addition of 1 mL culture medium well known to researchers in this field to each well, the cells were cultured in 5% incubator for 24 hours at 37° C., then the different concentration compounds and controls were added to each well. It should be noted that the added volume is not more than 0.5% of total volume. After completion of addition, the cells continued being cultured in incubator for one week, the culture medium was removed and washed by cold PBS of 1 mL once, and then fixed for 10 minutes at room temperature with 1% formalin, followed by wash with PBS of 1 mL. After fixation, stain was carried out with 0.1% crystal violet for 30 minutes. 0.1% crystal violet was recycled. The stained cells were washed gently with deionized water, dried at room temperature and kepted. The inhibition rate was calculated according to the foiling equation. The controls are Selumetinib (AZD6244), Gefitinib, Cisplatin.
Inhibition rate=number of left cells each treatment/number of left cells of untreated control×100%
At the concentration of 10 μM, the inhibition rate of compounds of this invention against all tested cell lines attached 90%-100%, some of them were further tested at lower concentration and the comparative bioassay was conducted with the controls selumetinib (AZD6244), gefitinib, Cisplatin at the same time, part of test results are listed in Table 55:
T24, prostate cancer cell lines LNCap
PC-3, lung cancer cell lines A549, H157
H460
H520, clon cancer cell lines HCT8, HCT116, RkO, the culture medium for all cell lines is RMPI-1640.
The inhibition rate of human leukemia HL-60 cells was evaluated by regular MTT method. The human leukemia HL-60 cells were picked up from cell incubator, after washed for twice using PBS, cells were digested by 0.25% trypsin, and then add medium to terminate the digestion. After cells were collected using centrifuge and re-suspended, counting cells under inverted microscope and adding medium to make a density which was 5×104 cells/mL. After 100 μL aliquots were added to each well of 96-well microtiter plates, cells were cultured in 5% incubator for overnight at 37° C., then the different concentration compounds were added to each well. After incubation for 48 h, MTT solution was added to each well and plates were then incubated for 4 h. The MTT tetrazolium was reduced to formazan by living cells. Then the formazan crystals were dissolved though adding DMSO to each well. The absorbance was read at 570 nm with a microplate reader.
Part of the test results are listed in Table 56:
Number | Date | Country | Kind |
---|---|---|---|
2013 1 0377438 | Aug 2013 | CN | national |
2013 1 0377457 | Aug 2013 | CN | national |
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/CN2014/084990 | 8/22/2014 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2015/027863 | 3/5/2015 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
20120088662 | Dietz | Apr 2012 | A1 |
20120149707 | Kim | Jun 2012 | A1 |
Number | Date | Country |
---|---|---|
102600164 | Jul 2012 | CN |
Entry |
---|
International Search Report received in PCT/CN2014/084990, dated Nov. 28, 2014. |
International Written Opinion received in PCT/CN2014/084990, dated Nov. 28, 2014. |
Number | Date | Country | |
---|---|---|---|
20170296508 A1 | Oct 2017 | US |